These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
677 related items for PubMed ID: 21094692
1. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA. Heemstra HE, Leufkens HG, Rodgers RP, Xu K, Voordouw BC, Braun MM. Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692 [Abstract] [Full Text] [Related]
2. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M, Shringarpure DT, Mardekian J, Cassino C, Coté T. Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137 [Abstract] [Full Text] [Related]
3. Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Talele SS, Xu K, Pariser AR, Braun MM, Farag-El-Massah S, Phillips MI, Thompson BH, Coté TR. Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615 [Abstract] [Full Text] [Related]
4. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O, Zhou Y. Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435 [Abstract] [Full Text] [Related]
5. The routes to orphan drug designation--our recent experience at the FDA. Lev D, Thorat C, Phillips I, Thomas M, Imoisili MA. Drug Discov Today; 2012 Feb; 17(3-4):97-9. PubMed ID: 22210120 [No Abstract] [Full Text] [Related]
6. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ. Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related]
10. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis. Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA. Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464 [Abstract] [Full Text] [Related]
11. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials. Pariser AR, Xu K, Milto J, Coté TR. Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390 [Abstract] [Full Text] [Related]
12. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Xu K, Coté TR. Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612 [Abstract] [Full Text] [Related]
17. Lessons learned from independent central review. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138 [Abstract] [Full Text] [Related]
18. Adopting orphan drugs--two dozen years of treating rare diseases. Haffner ME. N Engl J Med; 2006 Feb 02; 354(5):445-7. PubMed ID: 16452556 [No Abstract] [Full Text] [Related]
19. Promoting, improving and accelerating the drug development and approval processes. Graul AI. Drug News Perspect; 2008 Feb 02; 21(1):36-43. PubMed ID: 18301808 [Abstract] [Full Text] [Related]
20. The Orphan Drug Act: Restoring the Mission to Rare Diseases. Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA. Am J Clin Oncol; 2016 Apr 02; 39(2):210-3. PubMed ID: 26580246 [Abstract] [Full Text] [Related] Page: [Next] [New Search]